CD40 and Patent ductus arteriosus: To assess the cellular response to a CD40 agonist in combination with chemotherapy (hereafter referred to as chemoimmunotherapy), we analyzed cryopreserved Ficoll-isolated PBMCs from patients (n = 17) with PDA treated with gemcitabine and an agonistic anti-CD40 mAb (Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.145389DS1).